|
| Press Releases |
|
 |
|
| Wednesday, August 3, 2022 |
|
|
Zhaoke Ophthalmology Completed Patient Enrollments for the Phase III Clinical Trials of the Myopia Progression Treatment Drug NVK002 |
| Zhaoke Ophthalmology Limited ("Zhaoke Ophthalmology" or "the Company", SEHK: 6622), a leading ophthalmic pharmaceutical company dedicated to the research and development more info >> |
|
| Monday, November 15, 2021 |
|
|
兆科眼科获选于2021年美国眼科学会年会Eyecelerator@AAO上发表演讲 |
| 致力于眼科疗法的研究、开发及商业化，以满足巨大医疗需求缺口的领先眼科制药企业兆科眼科有限公司（「兆科眼科」；香港联交所股份代号：6622）获选于2021年11月11日在美国新奥尔良举行的2021年美国眼科学会年会Eyecelerator@AAO上发表演讲。 more info >> |
|
|
兆科眼科獲選於2021年美國眼科學會年會Eyecelerator@AAO上發表演講 |
| 致力於眼科療法的研究、開發及商業化，以滿足巨大醫療需求缺口的領先眼科製藥企業兆科眼科有限公司（「兆科眼科」；香港聯交所股份代號：6622）獲選於2021年11月11日在美國新奧爾良舉行的2021年美國眼科學會年會Eyecelerator@AAO上發表演講。 more info >> |
|
| Monday, May 24, 2021 |
|
|
兆科眼科(6622.HK)两项产品通过国家药监局药品注册现场核查及GMP符合性检查 |
| 致力于眼科疗法的研究、开发及商业化的眼科制药公司——兆科眼科有限公司(「兆科眼科」或「公司」；股份代号：6622)，宣布两项药品——贝美素噻吗洛尔滴眼液(在中国用于治疗青光眼的潜在首仿药 more info >> |
|
|
兆科眼科(6622.HK)兩項產品通過國家藥監局藥品註冊現場核查及GMP符合性檢查 |
| 致力於眼科療法的研究、開發及商業化的眼科製藥公司——兆科眼科有限公司(「兆科眼科」或「公司」；股份代號：6622)，宣佈兩項藥品——貝美素噻嗎洛爾滴眼液(在中國用於治療青光眼的潛在首仿藥 more info >> |
|
|
Two Products of Zhaoke Ophthalmology (6622.HK) Passes On-Site Inspection for Drug Registration by National Medical Products Administration and GMP Compliance Inspection by Guangdong Medical Products Administration |
| Zhaoke Ophthalmology Limited ("Zhaoke Ophthalmology" or the "Company"; stock code: 6622), an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Kincora Announces Shareholder Meeting Results
Dec 10, 2024 08:59 HKT/SGT
|
|
|
Friedman Institute Releases Report on "Analysis on Libyan Oil and Gas Supply - Italy's Strategic Role in Mediterranean Energy"
Dec 10, 2024 08:30: JST
|
|
|
Friedman Institute Releases Report on "Analysis on Libyan Oil and Gas Supply - Italy's Strategic Role in Mediterranean Energy"
Dec 10, 2024 07:30 HKT/SGT
|
|
|
Lexaria Reports: Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5
Dec 9, 2024 22:10 HKT/SGT
|
|
|
HAIN Premieres December 13, Showcasing the Power of Turkish Cinema
Dec 9, 2024 23:00 JST
|
|
|
Q2 Metals Drills 188.6 M Grading 1.56% Li2O, including 26 Metres of 2.03% Li2O, at the Cisco Lithium Property, James Bay, Quebec, Canada
Dec 9, 2024 21:52 HKT/SGT
|
|
|
Eastern River Pty Ltd Forecasts Strong Growth in the Global Corporate Bond Market in 2024, with Australian Bonds Also Showing Resilience
Dec 9, 2024 20:20 HKT/SGT
|
|
|
Fourteen new trains to drive first rail open access growth
Dec 9, 2024 20:10 JST
|
|
|
Hitachi to supply Japan's first SF6-free 300 kV circuit-breakers to Chubu Electric Power Grid
Dec 9, 2024 19:13 JST
|
|
|
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China
Dec 9, 2024 14:00: JST
|
|
|
NEC begins sale of 100G QSFP28 ZR4 single-fiber bi-directional optical transceiver
Dec 9, 2024 14:06 JST
|
|
|
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China
Dec 9, 2024 13:00 HKT/SGT
|
|
|
Hitachi, NTT Com Successfully Demonstrate World's First Real-Time Data Synchronization Over 600 km Using Storage
Virtualization Technology and IOWN APN
Dec 9, 2024 12:00 JST
|
|
|
Breaking Barriers in Data Communication: ULVAC & SAL join forces
Dec 9, 2024 9:00 JST
|
|
|
Business of IP Asia Forum and Entrepreneur Day Unlock IP and Innovation Potential
Dec 8, 2024 17:21 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
